What Are the Side Effects of Infusion for Osteoporosis?

Intravenous bisphosphonate infusions for osteoporosis, most commonly zoledronic acid given once a year, carry a well-documented set of side effects that range from a short-lived flu-like reaction experienced by roughly four in ten recipients to rare but serious complications involving the kidneys, jaw, or heart rhythm. Most people tolerate the infusion well and find that the temporary discomfort resolves within a few days, but several less common risks deserve attention before and after treatment. The picture is more nuanced than a simple side-effect list, because some reactions appear linked to how well the drug works, and some serious complications are largely preventable with proper screening.

The Flu-Like Reaction That Hits Within a Day or Two

The most talked-about side effect is the acute-phase reaction: fever, body aches, fatigue, headache, and sometimes nausea or joint swelling that begins within hours of the infusion and peaks over the first one to three days. In the large HORIZON fracture trial, about 42% of women who received zoledronic acid experienced some form of this reaction, compared with roughly 12% given a placebo.¹ The symptoms can feel like a sudden case of the flu. For most people, they fade within 72 hours and are significantly milder, or absent entirely, with subsequent annual infusions.

What is actually happening in your body is an immune flare. Zoledronic acid activates a specific subset of immune cells, which in turn release inflammatory signaling molecules like interferon-gamma and target monocytes for destruction.² This burst of immune activity produces the fever and aches. Think of it as your immune system briefly overreacting to the drug before settling down.

Does the Flu-Like Reaction Mean the Drug Is Working Better?

There is an interesting finding that people who experience the acute-phase reaction may actually get a larger benefit from zoledronic acid. Among women in the HORIZON trial who had the reaction and received the drug, vertebral fracture incidence was about 2.2%, compared with 4.3% in those who received the drug but did not have the reaction. The reduction in vertebral fracture risk was roughly twice as large in the group that felt sick afterward.¹ That does not mean you should hope for side effects, and researchers note the bone density gains were solid regardless of whether an acute-phase reaction occurred. But if you do feel lousy for a couple of days, it is at least somewhat reassuring.

Reducing the Post-Infusion Symptoms

Taking acetaminophen (Tylenol) around the time of infusion makes a meaningful difference. In a randomized trial, the proportion of patients who developed a clinically significant fever or needed rescue medication dropped from about 61% with placebo to roughly 40% with acetaminophen taken before and after the infusion.³ Most infusion centers will advise you to take acetaminophen before arriving and continue it on a schedule for two to three days afterward. Staying well hydrated before the infusion also helps. A statin drug (fluvastatin) was tested in the same trial and showed no benefit at all for preventing post-dose symptoms, so this is not a general anti-inflammatory strategy; acetaminophen specifically seems to blunt the reaction.

Kidney Concerns

Zoledronic acid is filtered through the kidneys, and protecting kidney function is one of the main safety considerations. That is why your doctor will check your kidney function with a blood test before scheduling the infusion, and the drug is not recommended for people with severely reduced kidney function. The infusion is also given slowly, typically over at least 15 minutes, specifically to reduce stress on the kidneys.

When kidney problems do occur, the most frequently reported issue in adverse-event databases is damage to the kidney’s filtering tubes, known as renal tubular necrosis. An analysis of adverse-event reports found this was the most commonly reported kidney-related side effect for osteoporosis patients on zoledronic acid, with the majority of these events arising either in the first 30 days after infusion or after more than a year of cumulative treatment.⁴ Serious kidney injury has historically been seen mainly in cancer patients receiving higher or more frequent doses, or in people who already had impaired kidneys or were taking other kidney-stressing medications. However, there have been case reports of kidney damage requiring dialysis even in patients without clear risk factors, which underscores the importance of pre-infusion kidney screening and post-infusion monitoring for everyone.⁵

Calcium Dropping Too Low

Bisphosphonates work by slowing the breakdown of bone, which shifts the balance of calcium in your body. In some cases, blood calcium can dip low enough to cause symptoms like tingling in the fingers, muscle cramps, or in severe cases, heart rhythm disturbances. Intravenous bisphosphonates carry a higher risk of this than the oral forms. The people most vulnerable are those who already have low vitamin D, impaired kidneys, or conditions affecting the parathyroid glands.⁶

This is largely a preventable complication. Standard practice is to check calcium and vitamin D levels before infusion and correct any deficiency first. You will almost certainly be told to take calcium and vitamin D supplements in the days surrounding the infusion, and often for the duration of treatment. When providers follow this protocol, clinically significant drops in calcium are uncommon.

Jaw Problems and Osteonecrosis

Medication-related osteonecrosis of the jaw (MRONJ) is one of the side effects that gets the most attention, even though it is rare in osteoporosis patients. MRONJ involves an area of jawbone that becomes exposed and fails to heal, usually after dental surgery like a tooth extraction. A large real-world cohort study found that non-cancer patients had much lower rates of MRONJ than cancer patients, who receive bisphosphonates at higher doses and more frequently.⁷ In cancer patients, the study found MRONJ developed in about 0.5% of zoledronic acid users. The rate in osteoporosis patients is considerably lower.

The practical takeaway: get any needed dental work done before starting infusion therapy, tell your dentist you are on a bisphosphonate, and maintain good oral hygiene. If you need a tooth extraction or jaw surgery while on treatment, your care team may plan accordingly to reduce risk. The condition is manageable when caught early, but prevention matters because treatment can be difficult.

Atypical Femoral Fractures

One of the more counterintuitive risks is that a drug designed to prevent fractures can, over long durations, contribute to a specific type of unusual fracture in the thigh bone. These “atypical femoral fractures” occur in the shaft of the femur, often with minimal or no trauma, and sometimes begin with a dull ache in the thigh weeks before the bone actually breaks. They are tied to the way bisphosphonates suppress bone remodeling: over many years, the normal process of replacing old bone with new bone slows so much that microdamage accumulates.

A large study found that the risk of atypical fracture climbed steeply with duration of bisphosphonate use. Compared to very short-term use, taking bisphosphonates for three to five years roughly nine-fold increased the risk, and eight or more years of use raised it more than forty-fold.⁸ It is worth stressing that the absolute risk remains small even at those durations; the relative increase sounds dramatic because the baseline rate is very low. In case series, atypical fractures have been reported in patients on both oral and intravenous bisphosphonates.⁹ Still, this risk is the primary reason doctors now discuss “drug holidays” after several years of treatment, and why any new or persistent thigh pain during bisphosphonate therapy should be reported promptly.

Heart Rhythm and Cardiovascular Effects

The relationship between zoledronic acid and heart rhythm, particularly atrial fibrillation, has been debated since early clinical trials hinted at a possible link. A meta-analysis of randomized trials in primary osteoporosis found a modest increase in overall cardiovascular events with zoledronic acid compared to placebo, driven mainly by a higher rate of arrhythmias. The risk of arrhythmia was about 30% higher than with placebo, though the risk of major adverse cardiovascular events like heart attack or stroke was not significantly elevated.¹⁰

When compared head-to-head with denosumab (a different injectable osteoporosis drug), zoledronic acid was associated with a modestly higher rate of atrial fibrillation in the first year of treatment.¹¹ Adverse-event database analyses have also flagged zoledronic acid as the bisphosphonate with the broadest range of reported cardiac rhythm disturbances. If you have a pre-existing heart rhythm condition, this is worth discussing with your doctor before choosing between infusion options, though the absolute risk increase remains small for most patients.

Eye Inflammation

A less well-known side effect is ocular inflammation. Bisphosphonates, particularly the intravenous forms, can trigger inflammation in the eye, which may present as pain, redness, light sensitivity, and blurred vision. These reactions generally show up within days of the infusion.¹² The inflammation can affect different structures of the eye, from the front chamber to the white of the eye. Case reports describe patients developing acute eye inflammation two to three days after zoledronic acid infusion for osteoporosis, with symptoms including eye pain, redness, and photophobia.¹³

This is rare, but if you develop eye symptoms in the week after an infusion, see an eye doctor promptly rather than waiting to see if it clears up. The inflammation responds well to treatment with steroid eye drops when caught early, but untreated eye inflammation can cause lasting problems.

Skin Reactions

Skin-related side effects are uncommon but span a wide spectrum. The milder end includes rashes, hives, and skin sensitivity to light. More concerning, though exceedingly rare, are severe reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis, which are serious conditions involving widespread skin blistering. These severe skin reactions occur in fewer than 1 in 10,000 cases across all bisphosphonates.¹⁴ There have also been case reports of diffuse skin rashes appearing a couple of days after zoledronic acid infusion even in patients with no history of allergies.¹⁵ Any widespread or blistering rash after infusion warrants immediate medical attention, as early recognition and stopping the drug are the most important steps.

Drug Holidays and Why They Matter for Side Effects

Unlike most medications, bisphosphonates bind directly to bone and stay there for years. This means the drug keeps working even after you stop receiving infusions, which opens the door to planned treatment breaks known as drug holidays. Current expert guidance suggests that after five or more years of bisphosphonate treatment, doctors should reassess whether to continue. For zoledronic acid specifically, a holiday of three to six years has been suggested for patients at lower fracture risk who have not broken a bone during treatment.¹⁶

Drug holidays are relevant to side effects because the rare complications like atypical femoral fractures and jaw osteonecrosis are tied to duration of exposure. Pausing treatment after an appropriate period reduces cumulative risk while the drug’s fracture-prevention effects persist in the skeleton. After the holiday, bone density and fracture risk are reassessed, and treatment is restarted if needed. This is different from denosumab, the other common injectable option, where stopping abruptly can lead to a rapid rebound in bone loss and even an increased fracture risk. Bisphosphonates, because they stick around in bone for so long, do not carry that same rebound concern.¹⁷

What Your Doctor Checks Before and After the Infusion

Much of the safety profile of zoledronic acid depends on what happens before the infusion even begins. A pre-infusion workup typically includes:

Kidney function: A blood test measuring creatinine clearance to confirm the kidneys can handle the drug.
Calcium and vitamin D: Low levels are corrected before the infusion to prevent hypocalcemia.
Dental health: Unresolved dental infections or planned jaw surgery may need to be addressed first to lower the risk of jaw osteonecrosis.
Hydration: You are typically asked to drink plenty of water beforehand, and fluids are often given during the infusion itself.

After the infusion, most people are monitored briefly and then sent home with instructions to stay hydrated and take acetaminophen if flu-like symptoms develop. Follow-up blood work to check kidney function and calcium is common in the days or weeks afterward, particularly after a first infusion. In clinical practice, most patients report that any side effects they experienced were mild and manageable with simple measures like pain relievers and fluids.¹⁸

How Zoledronic Acid Compares to Oral Bisphosphonates on Side Effects

If you are weighing an annual infusion against daily or weekly oral bisphosphonate pills, the side-effect profiles are genuinely different rather than one being clearly worse. Oral bisphosphonates are notorious for gastrointestinal problems: heartburn, esophageal irritation, and in rare cases, ulcers. These issues are essentially absent with the intravenous route because the drug bypasses the digestive tract entirely. On the other hand, the acute-phase flu-like reaction is largely an infusion-specific phenomenon. Oral users do not typically get hit with fever and body aches the way infusion recipients can.

The rare, duration-dependent complications like atypical femoral fractures and jaw osteonecrosis occur with both oral and intravenous bisphosphonates. The cardiovascular signals, particularly the arrhythmia question, have been studied more extensively with zoledronic acid, but there is no strong evidence that one route is clearly safer for the heart than the other. For kidney effects, the intravenous form poses a more direct and acute risk because a bolus of drug hits the kidneys at once, whereas oral forms are absorbed gradually. This is why the kidney function screening before infusion is so critical.

For people who struggle with the strict dosing requirements of oral bisphosphonates (taken on an empty stomach, remaining upright for 30 minutes, not eating for a period afterward), the once-yearly infusion can feel like a significant quality-of-life improvement. The trade-off is accepting a few days of possible flu-like discomfort in exchange for avoiding a year of daily or weekly pill-taking hassles. An annual zoledronic acid infusion increases bone density at the spine by roughly 6.7% and at the hip by about 5.1%, with vertebral fracture risk reduced by about 70% and hip fracture risk by roughly 41%.¹⁹ That efficacy context matters when weighing side effects, because the risks of untreated osteoporosis (broken hips, spinal fractures, loss of independence) are substantial.